The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Nehal J. Lakhani
Consulting or Advisory Role - Ikena Oncology; Innovent Biologics; SK Life Sciences
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Celgene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics; Innovent Biologics (Inst); Jounce Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Hendrik-Tobias Arkenau
Employment - Hospital Corporation of America
Honoraria - Bayer; BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER
Consulting or Advisory Role - Engitix; iOnctura
Research Funding - Sarah Cannon Research Institute
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Stefan N. Symeonides
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Ipsen (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; Ipsen; MSD
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Gennao Bio; Guidepoint Global; Kiyatec; Massive Bio; Medtronic; Merck; MimiVax; Novocure; PPD; Regeneron; tocagen; Xcures
Speakers' Bureau - Prime Oncology
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); FORMA Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Sapience Therapeutics (Inst); tocagen (Inst)
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics
 
Jim Rotolo
Employment - Sapience Therapeutics
Stock and Other Ownership Interests - Sapience Therapeutics
Patents, Royalties, Other Intellectual Property - Hold patents and have patents pending from discoveries and technology generated at Sapience Therapeutics
Travel, Accommodations, Expenses - Sapience Therapeutics
 
Gina Capiaux
Employment - Sapience Therapeutics
Stock and Other Ownership Interests - Sapience Therapeutics
Consulting or Advisory Role - Sapience Therapeutics
Research Funding - Sapience Therapeutics (Inst)
Travel, Accommodations, Expenses - Sapience Therapeutics
 
Rob Michel
Employment - Eating Recovery Center (I)
Stock and Other Ownership Interests - Eating Recovery Center (I); Johnson and Johnson; Sapience Therapeutics
Consulting or Advisory Role - Exicure; Sapience Therapeutics
 
Stephen Kaesshaefer
No Relationships to Disclose
 
Alice Susannah Bexon
Employment - Bexon Clinical Consulting
Leadership - Sapience Therapeutics; Vyriad
Stock and Other Ownership Interests - Sapience Therapeutics; Vyriad
Patents, Royalties, Other Intellectual Property - Patents for Sapience know-how relative to ST101
Travel, Accommodations, Expenses - Sapience Therapeutics; Vyriad
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Inspirna (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute